The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.
Identifieur interne : 000F54 ( PubMed/Checkpoint ); précédent : 000F53; suivant : 000F55The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.
Auteurs : S. Thobois [France] ; S. Corvaisier ; P. Mertens ; C. Di Guardo ; H. Mollion ; M. Guenot ; F. Rochefort ; G. Chazot ; M. Sindou ; E. BroussolleSource :
- European neurology [ 0014-3022 ] ; 2003.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Electric Stimulation Therapy, Electrodes, Implanted, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Postoperative Care, Subthalamic Nucleus (physiopathology).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents.
- drug effects : Neurologic Examination.
- physiopathology : Parkinson Disease, Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Aged, Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Electric Stimulation Therapy, Electrodes, Implanted, Female, Follow-Up Studies, Humans, Male, Middle Aged, Postoperative Care.
Abstract
The objective of this work was to precisely analyse the reduction of the antiparkinsonian treatment in 18 consecutive patients with Parkinson's disease (PD) operated on for bilateral subthalamic nucleus (STN) stimulation, first after 1 month of follow-up, then at 1 year postoperatively. Trihexyphenidyle, selegiline, entacapone, apomorphine and lisuride could be withdrawn shortly after starting STN electrical stimulation. The levodopa mean daily dose was reduced by 57% at 1 month after surgery and remained stable at 1 year. The mean ropinirole and bromocriptine daily dose decrements after surgery corresponded to 54 and 63%, respectively, at 1 month and to 77 and 40% at 1 year. At 12 months postoperatively, one third of the patients no longer received any antiparkinsonian drugs and the others were on monotherapy of either levodopa or dopamine agonists or received a combined treatment of a dopaminergic agonist and levodopa. In conclusion, STN stimulation allows a major reduction and simplification of antiparkinsonian treatment which can usually be achieved during the early postoperative period.
DOI: 67028
PubMed: 12464720
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:12464720Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.</title><author><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name><affiliation wicri:level="3"><nlm:affiliation>Neurological Department D, Neurological Hospital Pierre Wertheimer, Lyon, France. stephane.thobois@chu-lyon.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Neurological Department D, Neurological Hospital Pierre Wertheimer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Corvaisier, S" sort="Corvaisier, S" uniqKey="Corvaisier S" first="S" last="Corvaisier">S. Corvaisier</name></author><author><name sortKey="Mertens, P" sort="Mertens, P" uniqKey="Mertens P" first="P" last="Mertens">P. Mertens</name></author><author><name sortKey="Di Guardo, C" sort="Di Guardo, C" uniqKey="Di Guardo C" first="C" last="Di Guardo">C. Di Guardo</name></author><author><name sortKey="Mollion, H" sort="Mollion, H" uniqKey="Mollion H" first="H" last="Mollion">H. Mollion</name></author><author><name sortKey="Guenot, M" sort="Guenot, M" uniqKey="Guenot M" first="M" last="Guenot">M. Guenot</name></author><author><name sortKey="Rochefort, F" sort="Rochefort, F" uniqKey="Rochefort F" first="F" last="Rochefort">F. Rochefort</name></author><author><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G" last="Chazot">G. Chazot</name></author><author><name sortKey="Sindou, M" sort="Sindou, M" uniqKey="Sindou M" first="M" last="Sindou">M. Sindou</name></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12464720</idno><idno type="pmid">12464720</idno><idno type="doi">67028</idno><idno type="wicri:Area/PubMed/Corpus">001139</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001139</idno><idno type="wicri:Area/PubMed/Curation">001098</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001098</idno><idno type="wicri:Area/PubMed/Checkpoint">001098</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001098</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.</title><author><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name><affiliation wicri:level="3"><nlm:affiliation>Neurological Department D, Neurological Hospital Pierre Wertheimer, Lyon, France. stephane.thobois@chu-lyon.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Neurological Department D, Neurological Hospital Pierre Wertheimer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Corvaisier, S" sort="Corvaisier, S" uniqKey="Corvaisier S" first="S" last="Corvaisier">S. Corvaisier</name></author><author><name sortKey="Mertens, P" sort="Mertens, P" uniqKey="Mertens P" first="P" last="Mertens">P. Mertens</name></author><author><name sortKey="Di Guardo, C" sort="Di Guardo, C" uniqKey="Di Guardo C" first="C" last="Di Guardo">C. Di Guardo</name></author><author><name sortKey="Mollion, H" sort="Mollion, H" uniqKey="Mollion H" first="H" last="Mollion">H. Mollion</name></author><author><name sortKey="Guenot, M" sort="Guenot, M" uniqKey="Guenot M" first="M" last="Guenot">M. Guenot</name></author><author><name sortKey="Rochefort, F" sort="Rochefort, F" uniqKey="Rochefort F" first="F" last="Rochefort">F. Rochefort</name></author><author><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G" last="Chazot">G. Chazot</name></author><author><name sortKey="Sindou, M" sort="Sindou, M" uniqKey="Sindou M" first="M" last="Sindou">M. Sindou</name></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name></author></analytic><series><title level="j">European neurology</title><idno type="ISSN">0014-3022</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Combined Modality Therapy</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Electric Stimulation Therapy</term><term>Electrodes, Implanted</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Postoperative Care</term><term>Subthalamic Nucleus (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Combined Modality Therapy</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Electric Stimulation Therapy</term><term>Electrodes, Implanted</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Postoperative Care</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this work was to precisely analyse the reduction of the antiparkinsonian treatment in 18 consecutive patients with Parkinson's disease (PD) operated on for bilateral subthalamic nucleus (STN) stimulation, first after 1 month of follow-up, then at 1 year postoperatively. Trihexyphenidyle, selegiline, entacapone, apomorphine and lisuride could be withdrawn shortly after starting STN electrical stimulation. The levodopa mean daily dose was reduced by 57% at 1 month after surgery and remained stable at 1 year. The mean ropinirole and bromocriptine daily dose decrements after surgery corresponded to 54 and 63%, respectively, at 1 month and to 77 and 40% at 1 year. At 12 months postoperatively, one third of the patients no longer received any antiparkinsonian drugs and the others were on monotherapy of either levodopa or dopamine agonists or received a combined treatment of a dopaminergic agonist and levodopa. In conclusion, STN stimulation allows a major reduction and simplification of antiparkinsonian treatment which can usually be achieved during the early postoperative period.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12464720</PMID><DateCreated><Year>2002</Year><Month>12</Month><Day>04</Day></DateCreated><DateCompleted><Year>2003</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-3022</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>1</Issue><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>European neurology</Title><ISOAbbreviation>Eur. Neurol.</ISOAbbreviation></Journal><ArticleTitle>The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.</ArticleTitle><Pagination><MedlinePgn>59-63</MedlinePgn></Pagination><Abstract><AbstractText>The objective of this work was to precisely analyse the reduction of the antiparkinsonian treatment in 18 consecutive patients with Parkinson's disease (PD) operated on for bilateral subthalamic nucleus (STN) stimulation, first after 1 month of follow-up, then at 1 year postoperatively. Trihexyphenidyle, selegiline, entacapone, apomorphine and lisuride could be withdrawn shortly after starting STN electrical stimulation. The levodopa mean daily dose was reduced by 57% at 1 month after surgery and remained stable at 1 year. The mean ropinirole and bromocriptine daily dose decrements after surgery corresponded to 54 and 63%, respectively, at 1 month and to 77 and 40% at 1 year. At 12 months postoperatively, one third of the patients no longer received any antiparkinsonian drugs and the others were on monotherapy of either levodopa or dopamine agonists or received a combined treatment of a dopaminergic agonist and levodopa. In conclusion, STN stimulation allows a major reduction and simplification of antiparkinsonian treatment which can usually be achieved during the early postoperative period.</AbstractText><CopyrightInformation>Copyright 2003 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thobois</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurological Department D, Neurological Hospital Pierre Wertheimer, Lyon, France. stephane.thobois@chu-lyon.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corvaisier</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Di Guardo</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mollion</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Guenot</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rochefort</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Chazot</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sindou</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Broussolle</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Neurol</MedlineTA><NlmUniqueID>0150760</NlmUniqueID><ISSNLinking>0014-3022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004599" MajorTopicYN="Y">Electric Stimulation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004567" MajorTopicYN="Y">Electrodes, Implanted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="Y">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>12</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>20</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>12</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12464720</ArticleId><ArticleId IdType="pii">67028</ArticleId><ArticleId IdType="doi">67028</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><noCountry><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G" last="Chazot">G. Chazot</name><name sortKey="Corvaisier, S" sort="Corvaisier, S" uniqKey="Corvaisier S" first="S" last="Corvaisier">S. Corvaisier</name><name sortKey="Di Guardo, C" sort="Di Guardo, C" uniqKey="Di Guardo C" first="C" last="Di Guardo">C. Di Guardo</name><name sortKey="Guenot, M" sort="Guenot, M" uniqKey="Guenot M" first="M" last="Guenot">M. Guenot</name><name sortKey="Mertens, P" sort="Mertens, P" uniqKey="Mertens P" first="P" last="Mertens">P. Mertens</name><name sortKey="Mollion, H" sort="Mollion, H" uniqKey="Mollion H" first="H" last="Mollion">H. Mollion</name><name sortKey="Rochefort, F" sort="Rochefort, F" uniqKey="Rochefort F" first="F" last="Rochefort">F. Rochefort</name><name sortKey="Sindou, M" sort="Sindou, M" uniqKey="Sindou M" first="M" last="Sindou">M. Sindou</name></noCountry><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000F54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:12464720
|texte= The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:12464720" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |